{"abstract": "Novartis has bought U.S.-based Protez Pharmaceuticals in a deal worth up to $400 million, Reuters reported. The deal would give Novartis rights to an antibiotic which could be used to fight superbugs such as MRSA, the Swiss drugmaker said.", "web_url": "https://dealbook.nytimes.com/2008/06/04/novartis-nabs-protez-for-400-million/", "snippet": "", "lead_paragraph": "Novartis has bought U.S.-based Protez Pharmaceuticals in a deal worth up to $400 million, Reuters reported. The deal would give Novartis rights to an antibiotic which could be used to fight superbugs such as MRSA, the Swiss drugmaker said.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Novartis Nabs Protez for $400 Million", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2008-06-04T10:55:33+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4cf31323-6803-5acb-a6d0-2366a6afe075", "word_count": 72, "uri": "nyt://article/4cf31323-6803-5acb-a6d0-2366a6afe075"}